Beast Philanthropy Featured Light AI's Life-Saving Technology in February 16, 2025 Episode
VANCOUVER, BC, Feb. 18, 2025 /CNW/ - Light AI Inc. ("Light AI" or the "Company") (CBOE CA: ALGO / FSE: 0HC), a global healthcare technology company focused on developing artificial intelligence health diagnostic and wellness solutions, is partnering with MrBeast Industries to launch a Streptococcus A (Strep A) test donation initiative in Africa. The collaboration is featured in a Beast Philanthropy video, which premiered February 16, 2025, on YouTube.
Light AI logo (CNW Group/Light AI Inc.)
Businessman and social media star, Jimmy Donaldson (aka "MrBeast") operates the world's largest YouTube channel and is known for his viral philanthropic projects. His charity channel, Beast Philanthropy, donates 100% of its revenue to charitable causes, tackling urgent global issues.
Through this partnership, the Company will donate AI-powered Strep A tests, enabling faster and more accessible diagnosis in underserved regions of Africa. Viral and GAS pharyngitis affects over 600 million people annually, and if untreated, can lead to Rheumatic Heart Disease (RHD)—a fatal condition with an annual global economic burden exceeding $1 trillion. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs.
"We're excited to partner with Light AI to help stop rheumatic heart disease at its root cause which is Strep A. Their AI-powered technology makes early detection accessible and affordable, helping save lives in communities that need it most," stated Donaldson.
"We are honored to partner with MrBeast to address and enhance health and wellness in Africa. Strep A infects up to 600 million people annually and is the root cause of rheumatic heart disease, which causes up to 350,000 deaths annually. Light AI is tackling the root cause of a serious yet preventable disease," stated Peter Whitehead, Chief Executive Officer of Light AI. "Light AI's technology is simple, affordable, accessible, and powerful, built to detect Strep A instantly, and its immediate detection is the answer to preventing life-threatening conditions like rheumatic heart disease and making a positive impact."
About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC)
Light AI Inc. is a healthcare company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A—to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5B smartphones that exist in the world today.
In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The Company's algorithm generated pre-Federal Drug Administration (FDA) results were in the range of the "Gold Standard" swab culture currently used for diagnosing GAS achieving a 96.57% accuracy rate that is and a Negative Predictive Value (NPV) of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.
ON BEHALF OF THE COMPANY
"George Reznik"
George Reznik Chief Financial Officer
For more information, please contact the Company at 604-307-6800 or visit https://light.ai/.
Website:https://light.ai/ LinkedIn: LinkedIn/company/Light AI X (Formerly Twitter): @lightaihealth
Forward-Looking Information:
This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the contributions to be made by the Company's partnership with MrBeast, the anticipated inflection of the business, the opportunity related to the commercialization of Light AI's software and other offerings, and other statements that contain words such as "believe," "expect," "project," "should," "seek," "anticipate," "will," "intend," "positioned," "risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may affect any of the Company's forward-looking statements, please refer to the Company's long form prospectus dated December 17, 2024 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at www.sedarplus.ca). Light AI disclaims any intention or obligation to update or revise any forward-looking information contained in this new release, whether as a result of new information, future events or otherwise, unless required by applicable law. The forward-looking information included in this news release is expressly qualified in its entirety by this cautionary statement.
